Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Chemotherapy in Stage N3 NPC
NCT04220528Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2019
- Primary completion
- Jun 2023
- Modality
- Reversible Covalent Inhibitors, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, tegafur + gimeracil + oteracil in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
capecitabinetegafur + gimeracil + oteracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04220528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220528.